Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Wesana Health Holdings Inc. (C:WESA)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEDAR
Company Contact
Address: 82 Richmond Street East
The Canadian Venture Building
TORONTO ON M5C 1P1
Tel: N/A
Website: N/A
IR: N/A
Key People
N/A    
Business Overview
Wesana Health Holdings Inc is a Canada-based life science company. The Company is engaged in development and delivery of psychedelic and naturally sourced therapies to treat traumatic brain Injury related depressive disorder, anxiety and migraines through drug development and predictive diagnostics. The Company is also engaged in care development through its therapies and patent-pending protocols, and in care delivery through activating a multidisciplinary, technology-supported clinical model. Its SANA-013 is a novel composition and method of use that provides sustained effects and benefit over time. The Company's novel and proprietary depression treatment protocol that includes a single high dose of psilocybin followed by a maintenance regimen of a micro dose of psilocybin combined with cannabidiol, significantly reduced depressive behaviors in a validated animal model.
Financial Overview
For the six months ended 30 June 2022, Wesana Health Holdings Inc revenues increased from $0K to $2K. Net loss before extraordinary items increased 41% to $6.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administration increase from $742K to $2.2M (expense), Share based payments increase from $748K to $1.8M (expense).
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.35M as of Jun 30, 2022
EBITDA (TTM): -$22.02M as of Jun 30, 2022
Net annual income (TTM): -$44.85M as of Jun 30, 2022
Free cash flow (TTM): -$17.08M as of Jun 30, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 20,083,943 as of Jun 30, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization